Israeli hashish inhaler firm Syqe Medical has confirmed that it’s shedding 50 workers representing one third of its workforce. Syqe has developed inhaling applied sciences to manage measured and constant doses of medical hashish. The corporate was based in 2011 by Perry Davidson and is managed by CEO Hagit Kamin.
Davidson based the corporate to resolve one of many main issues with hashish – the shortage of uniformity between totally different doses. Even when the hashish itself could be replicated, that means that the crops are at all times the identical and processed in the identical method, a deeper inhalation can change the best way the substance impacts sufferers, introducing a component of unpredictability, which might hurt the standard of remedy. Syqe’s inhaler was developed to permit for a exact and measured dose, and within the course of has been in a position to obtain effectiveness even with small doses.
RELATED ARTICLES
Syqe begins advertising and marketing medical hashish inhaler
In 2019-2021, there was nice enthusiasm available in the market about the opportunity of administering hashish in a fashion just like prescription drugs, and Syqe’s expertise was one of the vital promising within the area. At the moment, the corporate nonetheless reviews income, however the emphasis on measured and exact inhalation is just a really particular area of interest available in the market.
The corporate presently stresses not solely dose measurements, but in addition the opportunity of utilizing its product to attain outcomes with a comparatively low dosage, whereas minimizing uncomfortable side effects.
Cooperation in Israel and Australia
A number of months in the past, the corporate introduced a collaboration with the Australian Division of Veterans’ Affairs (DVA), during which the division absolutely backed Syqe’s inhaler. The approval follows Syqe’s collaboration with Israel’s Ministry of Protection, during which the inhaler has been supplied to hundreds of sufferers, disabled throughout navy service, and affected by continual ache and post-traumatic stress dysfunction (PTSD). Syqe had a earlier settlement in Australia, during which its inhaler is supplied to victims of labor accidents.
It was beforehand reported that Syqe was to be offered to tobacco firm Philip Morris, which is certainly one of its buyers together with Retallix founders Barry Shaked and Brian Cooper, OurCrowd, Shavit Capital, the Martin Bauer Group’s PRM funding arm and others. Philip Morris does have an choice to progressively purchase Syqe primarily based on milestones.
Syqe mentioned, “Syqe is adjusting the corporate’s construction in the course of the second part of the scientific trial and is accordingly making changes to the workforce construction, primarily within the growth division. Specializing in the scientific course of is a major a part of realizing the corporate’s objectives, together with FDA approval, and accordingly, the corporate will deepen its assets on this space. As well as, Saiki will proceed to develop its actions in backed markets, together with Israel.”
Printed by Globes, Israel enterprise information – en.globes.co.il – on July 17, 2025.
© Copyright of Globes Writer Itonut (1983) Ltd., 2025.
